Gene test to predict liver cancer immunotherapy response
Part of Cancer, Digestive system clinical trials.
This study looks at a genetic test that may predict how well liver cancer patients respond to combination treatment with targeted therapy and immunotherapy. If eligible, your stored tumor tissue will be analyzed to see if a specific gene pattern can tell whether this treatment works for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with hepatocellular carcinoma (a common type of liver cancer) and had it confirmed by a biopsy (tissue sample) after surgery or a needle procedure.
- You have already received combination treatment with a targeted drug and an immunotherapy drug after your biopsy or surgery.
- You have stored tumor tissue (either from surgery or a needle biopsy) that can be used for genetic analysis.
- You have tumors that can be measured on a scan, and your doctor can tell if the cancer is stable, shrinking, or growing during the study.
- You must not have other active cancers (except certain cured ones), severe organ problems, uncontrolled infections, or autoimmune disease requiring strong immune-suppressing medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at people with advanced liver cancer (HCC) that cannot be removed by surgery. Researchers want to see if certain markers in your blood or tumor can help predict how well you respond to a combination of chemotherapy delivered directly to the liver and immunotherapy. If you join, you will receive the planned treatment and provide additional blood and tissue samples for analysis.
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
This study looks at blood and tissue samples from people with liver cancer to find markers that can predict how well treatment works and whether the cancer might come back. It may help doctors personalize treatment and follow-up care.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This trial aims to discover new immune system targets on liver cancer cells and other tumors to develop better immunotherapies. Researchers will analyze tumor samples to find these targets, which could lead to more effective treatments.
This study looks at blood cells from people with liver cancer (HCC) to see if we can predict early whether immunotherapy will work for them. It's a research study that involves blood tests during your normal care.
Hear when a new Primary Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.